Clinical trials at Memorial Sloan Kettering Cancer Center may give you access to new therapies that aren’t widely available. These research studies evaluate the safety and effectiveness of new ways to diagnose and treat primary brain tumors. They can also give your treatment team information about your current plan of care.

Because doctors from different disciplines work together closely through our collaborative Brain Tumor Center, many of our clinical trials combine different treatment approaches, such as radiation therapy and chemotherapy. These aggressive approaches show promise for improving the treatment of many types of brain tumors.

Our experts can help determine which clinical trial is right for you, including some of our newly opened clinical trials:

• 19-346 A Phase II/III Study of Regorafenib, Paxalisib, and VAL-083 versus Standard Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma (GBM AGILE)
• 20-901 A Phase II Study of Pembrolizumab, Olaparib, and Temozolomide in Patients with Glioma
• 22-187 A Phase I Study to Evaluate the CNS-Penetrant EGFR/ERBB1 Inhibitor ERAS-801 in Patients with Recurrent Glioblastoma
• 14-184 A Phase I/II Study of Ibrutinib in Patients with Recurrent or Persistent CNS Lymphoma
• 22-258 An Open-Label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants with Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III
• 22-366 A Phase I Study of Vorasidenib with Pembrolizumab Immunotherapy Recurrent or Persistent IDH-1 Mutant Astrocytomas

As a member of the North American Brain Tumor Coalition, we offer qualified patients access to several clinical trials sponsored by the National Cancer Institute.